HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
Conditions
Keywords
HER2 Positive Gastric Cancer, HER2 Positive gastroesophageal adenocarcinoma
Brief summary
TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase 1/2 study that aims to establish safety, maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 as a monotherapy, and in combination with pembrolizumab, in subjects with HER2 positive gastric and gastroesophageal adenocarcinoma.
Detailed description
The TAC technology is a novel approach to modifying T cells, herein referred to as TAC T cells, and using them in the treatment of solid tumors. TAC T cells are produced through genetic engineering, incorporating TAC receptors into a patient's own T cells. This redirects these enhanced T cells to specific cancer antigens, and upon recognition, activates them through the natural signaling pathways of the endogenous TCR. In the TAC01-HER2 engineered T cell product; TAC T cells recognize the HER2 protein present on the surface of tumor cells, and eradicate them. Consequently, it is hypothesized TAC01-HER2 will be potentially safe and effective in treating patients with HER2+ solid tumors and provide a clinically meaningful therapeutic benefit in patient populations with high unmet medical need. This is a first-in-human study investigating TAC01-HER2 to evaluate the safety, MTD or RP2D, PK, and efficacy in subjects with HER2+ solid tumors who have been treated after at least 2 lines of prior therapy in Phase 1 and after at least 2 lines and no more than 4 lines of prior therapy in Phase 2. In Phase 1, escalating doses of TAC01-HER2 will be evaluated to identify the RP2D using the classic keyboard design method. The monotherapy arm will treat all subjects with HER2-positive solid tumors that meet the eligibility criteria (completed). The combination arm will treat all 2+ or 3+ HER2-positive subjects with gastric or gastroesophageal AC who meet the eligibility criteria. In Phase 2, dose expansion groups will further evaluate the efficacy, safety, and PK of the MTD or RP2D for TAC01-CLDN18.2 in subjects with gastric and esophageal adenocarcinoma. In Phase 2, a Simon 3-stage design will be used to enroll up to 36 subjects in Group A (monotherapy arm) and 34 subjects in Group B (combination arm). In summary: * Phase I monotherapy arm: Dose escalation in any HER2-positive solid tumor (completed). * Phase I combination therapy arm: Dose escalation in combination with pembrolizumab in 2+ or 3+ HER2-positive gastric and gastroesophageal adenocarcinoma * Phase II: Dose expansion cohorts: 2+ or 3+ HER2-positive gastric or gastroesophageal adenocarcinoma treated with TAC01-HER2 as a monotherapy (Group A) or in combination with pembrolizumab (Group B).
Interventions
BIOLOGICALTAC01-HER2
TAC01-HER2 and: * fludarabine and cyclophosphamide, or * clofarabine and cyclophosphamide, or * bendamustine, or * cyclophosphamide
BIOLOGICALTAC01-HER2 plus pembrolizumab
TAC01-HER2 plus pembrolizumab and: * fludarabine and cyclophosphamide, or * clofarabine and cyclophosphamide, or * bendamustine, or * cyclophosphamide
Sponsors
Merck Sharp & Dohme LLC
Triumvira Immunologics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
In Phase 1, escalating doses of TAC01-HER2 will be evaluated to identify the RP2D of the monotherapy arm and the combination arm using the classic keyboard design. In Phase 2, dose expansion groups will further evaluate the safety, efficacy, and PK of the MTD or RP2D for TAC01-HER2 as a monotherapy and in combination with pembrolizumab in subjects with gastric and gastroesophageal adenocarcinoma.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written informed consent. 2. Age ≥ 18 years at the time of informed consent. 3. For Phase 1 and Phase 2: * Phase 1 monotherapy (completed): HER2 1+, 2+, 3+ by IHC by central laboratory confirmation * Phase 1 combination therapy and Phase 2: HER2 2+, 3+ by IHC and FISH by central laboratory confirmation 4. Histologically confirmed advanced, metastatic, unresectable solid tumors (regardless of PD-L1 expression levels; Phase 1 monotherapy) and histologically confirmed advanced, metastatic, unresectable gastric or esophageal adenocarcinoma (regardless of PD-L1 expression levels for Phase 1 combination therapy and Phase 2) after at least 2 prior lines of therapy (Phase 1) or after at least 2 and no more than 4 prior lines of therapy (Phase 2). 1. HER2+ incurable malignancies for which no standard-of-care HER2 targeted therapy exists may be enrolled regardless of the number of prior treatment lines, as long as in the opinion of the investigator the subject would be unlikely to tolerate or derive clinically meaningful benefit from other available treatment options. 2. For breast cancer subjects, both prior lines of therapy must have included HER2-targeted agents per current standard-of-care. 3. Subjects with solid tumors with genetic alterations and mutations (such as BRAF, BRCA, EGFR mutations, and ALK translocation) where approved targeted therapies were available to their specific cancers must have been previously treated with such approved therapies or refused such approved targeted therapy for their cancers prior to enrollment, or in the opinion of the investigator would be unlikely to tolerate or derive clinically meaningful benefit from these standard-of-care therapies. 5. Measurable disease per RECIST 1.1 at time of enrollment. 6. ECOG performance status of 0 or 1 at Screening. 7. Life expectancy of at least 12 weeks. 8. Adequate organ and bone marrow reserve function. 9. Recovery to Grade ≤1 or Baseline for any toxicities due to previous therapy. 10. Adequate vascular access for leukapheresis. 11. Negative pregnancy test and use of highly effective contraception. 12. Undetectable HBV viral load. 13. HCV viral load is undetectable.
Exclusion criteria
1. Intolerant to any component of TAC01-HER2. 2. Prior treatment with any of the following: 1. Adoptive cell transfer of any kind, including CAR T cells 2. Gene therapy 3. Investigational medicinal product within 5 half-lives or 21 days prior to leukapheresis, whichever is shorter. 4. Receipt of a live or live-attenuated vaccine within 30 days prior to study treatment. 5. Monoclonal antibody (mAb), including PD-1 and PD-L1, therapies within 21 days prior to leukapheresis. 6. Radiation within 28 days prior to enrollment. Palliative radiation is allowed up to 14 days prior to enrollment if non-irradiated lesions are present. 7. Chemotherapy or targeted small molecule therapy within 14 days prior to leukapheresis, or within 7 days prior to leukapheresis for erlotinib, gefitinib, afatinib, or crizotinib. 8. Colony stimulating factors, including granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin, and other hematopoietic cytokines, within 14 days prior to leukapheresis. 9. Immunosuppressive medication within 14 days or corticosteroid treatment \< 72 hours prior to enrollment. 10. History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. (Brain metastasis - non-progressive or previously treated and currently stable - are permitted.) 11. Active inflammatory neurological disorders (e.g., Guillain-Barre Syndrome, amyotrophic lateral sclerosis, multiple sclerosis). 12. Active autoimmune disease (e.g., lupus, rheumatoid arthritis, Sjogren's syndrome) requiring systemic disease modifying agents in the past 2 years. 13. Active or uncontrolled hepatitis B or C (HCV ribonucleic acid \[RNA\] positive) infection or any history of or active human immunodeficiency virus (HIV) infection. 14. Uncontrolled, acute, or life-threatening bacterial, viral, or fungal infection. Subjects with ongoing use of prophylactic antibiotics, antifungals, or antivirals are eligible if no evidence of active infection. 15. Class III or IV heart failure (as defined by the New York Heart Association - NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease within 6 months prior to Screening. 16. Cardiac arrhythmia not controlled by medical management. 17. Clinically significant thrombotic events within 6 months prior to leukapheresis and/or inability to stop anti-coagulation for at least 2 weeks prior to TAC01-HER2 infusion. 18. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, non-metastatic squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. 19. Pregnant or lactating. 20. As determined by the Investigator, any uncontrolled medical, psychological, familial, sociological, or geographical condition(s) that do(es) not permit compliance with the protocol. 21. Participation in or has participated in a study using an investigational device within 4 weeks prior to study treatment.. 22. Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate, in the opinion of the treating investigator. 23. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study. Combination Arm Only Specific Exclusions: 24. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients. 25. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE). 26. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment. 27. Has received radiation therapy to the lung that is \>30 Gy within 6 months of the first dose of trial treatment. 28. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. 29. Has history of an allogeneic stem cell transplant or a solid organ transplant. 30. Has a history of radiation pneumonitis. (Note: Cannot receive prior radiotherapy within 2 weeks of start of pembrolizumab. Note: Participants must have recovered from all radiation-related toxicities and not require corticosteroids. A 1-week washout is permitted for palliative radiation \[≤2 weeks of radiotherapy\] to non-CNS disease).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1: Incidence of Dose Limiting Toxicities (DLTs) | 28 days | A DLT is defined as: * Grade 4 or 5 events determined by the Investigator to be related to the investigational product, with the exception of Grade 4 laboratory abnormalities that are rapidly reversible or correctable without substantial safety concerns. * Grade ≥3 TAC T cell-associated acute infusion reactions persisting for ≥24 hours * Grade ≥3 TAC T cell-associated CRS or neurotoxicity persisting for ≥72 hours * Grade ≥3 cardiovascular or pulmonary toxicity persisting for ≥72 hours * Grade ≥3 immune-related toxicities * Grade ≥3 organ toxicities or non-hematologic toxicities that do not improve to baseline within 7 days * Clinically consequential Grade ≥3 neutropenia or thrombocytopenia lasting ≥30 days from TAC01-HER2 administration. Clinically consequential is defined as febrile neutropenia, serious infection, or bleeding events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1: Evaluate Overall Response Rate (ORR) | 24 months | Defined as the percentage of treated subjects with a complete or partial response (CR or PR) as assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. |
| Phase 1: Evaluate Duration of Response (DoR) | 24 months | Defined as time from first response to disease progression, end of study, start of another anticancer therapy, or death |
| Phase 1: Evaluate Overall Survival (OS) | 6 months | Defined as participants alive after 6 months |
| Phase 1: Determine Recommended Phase 2 Dose (RP2D) for TAC01-HER2 Monotherapy | Up to 28 Days Post TAC01-HER2 infusion | RP2D was determined by the Data and Safety Monitoring Committee using the keyboard design method (\<95% chance that the DLT rate exceeds 30%). |
| Phase 1: Progression-Free Survival (PFS) or Time to Progression (TTP) | 24 months | Defined as time from infusion to disease progression or death from any cause |
| Phase 1: Cmax of TAC01-HER2 (Pharmacokinetics; PK) | Pre-treatment, days 3, 4 or 5, 8, 11, 14 or15, 18, 21 or 22, 25, 29, 42, months 3, 6, 9, 12, 18, 24 or end of study, and at the confirmatory progressive disease visit | Defined as the maximum concentration of TAC T cells after infusion; assessed by vector copy number |
| Phase 1 and Phase 2: Tmax of TAC01-HER2 (PK) | Pre-treatment, days 3, 4 or 5, 8, 11, 14 or15, 18, 21 or 22, 25, 29, 42, months 3, 6, 9, 12, 18, 24 or end of study, and at the confirmatory progressive disease visit | Defined as the the first study day the Cmax is reached |
| Phase 1: Evaluate Disease Control Rate (DCR) | 24 months | Defined as the percentage of treated subjects with stable disease (SD), PR, and CR as assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST)Version 1.1. |
Countries
Canada, United States
Participant flow
Pre-assignment details
In addition to the 23 subjects who were assigned to groups, 5 additional subjects were enrolled but not not assigned to groups: * 3 died before group assignment * 2 failed to meet pre-treatment inclusion criteria
Participants by arm
| Arm | Count |
|---|---|
| TAC01-HER2 DL1 Lymphodepletion followed by TAC01-HER2 as a single IV infusion, with a potential for a second dose administration.
TAC01-HER2: 1-3x10\^5 TAC01-HER2 and:
* fludarabine and cyclophosphamide, or
* cyclophosphamide | 4 |
| TAC01-HER2 DL2 Lymphodepletion followed by TAC01-HER2 as a single IV infusion, with a potential for a second dose administration.
TAC01-HER2: 6-8x10\^5 TAC01-HER2 and:
* fludarabine and cyclophosphamide, or
* cyclophosphamide | 4 |
| TAC01-HER2 DL3 Lymphodepletion followed by TAC01-HER2 as a single IV infusion, with a potential for a second dose administration.
TAC01-HER2: 1-3x10\^6 TAC01-HER2 and:
* fludarabine and cyclophosphamide, or
* cyclophosphamide | 3 |
| TAC01-HER2 DL4 Lymphodepletion followed by TAC01-HER2 as a single IV infusion, with a potential for a second dose administration.
TAC01-HER2: 6-8x10\^6 TAC01-HER2 and:
* fludarabine and cyclophosphamide, or
* cyclophosphamide | 12 |
| Total | 23 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Death | 0 | 0 | 0 | 0 | 3 |
| Overall Study | failed to meet pre-treatment inclusion criteria | 0 | 0 | 0 | 0 | 2 |
Baseline characteristics
| Characteristic | Total | TAC01-HER2 DL4 | TAC01-HER2 DL3 | TAC01-HER2 DL2 | TAC01-HER2 DL1 |
|---|---|---|---|---|---|
| Age, Continuous | 59 years | 59 years | 52 years | 61.5 years | 65.5 years |
| Bridging therapy No | 10 Participants | 2 Participants | 3 Participants | 3 Participants | 2 Participants |
| Bridging therapy Yes | 13 Participants | 10 Participants | 0 Participants | 1 Participants | 2 Participants |
| Cancer type Breast | 3 Participants | 1 Participants | 2 Participants | 0 Participants | 0 Participants |
| Cancer type Gastric | 6 Participants | 4 Participants | 0 Participants | 1 Participants | 1 Participants |
| Cancer type Other | 14 Participants | 7 Participants | 1 Participants | 3 Participants | 3 Participants |
| Eastern Cooperative Oncology Group (ECOG) performance status 0 | 10 Participants | 5 Participants | 2 Participants | 2 Participants | 1 Participants |
| Eastern Cooperative Oncology Group (ECOG) performance status 1 | 13 Participants | 7 Participants | 1 Participants | 2 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 20 Participants | 10 Participants | 2 Participants | 4 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 3 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Asian | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Black | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Other | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Race White | 21 Participants | 11 Participants | 3 Participants | 3 Participants | 4 Participants |
| Sex: Female, Male Female | 15 Participants | 9 Participants | 1 Participants | 1 Participants | 4 Participants |
| Sex: Female, Male Male | 8 Participants | 3 Participants | 2 Participants | 3 Participants | 0 Participants |
| Stage of disease at screening Stage III | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Stage of disease at screening Stage IV | 19 Participants | 10 Participants | 2 Participants | 3 Participants | 4 Participants |
| Stage of disease at screening Unknown | 3 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 4 | 0 / 4 | 2 / 3 | 5 / 12 | 4 / 5 |
| other Total, other adverse events | 4 / 4 | 4 / 4 | 3 / 3 | 12 / 12 | 3 / 5 |
| serious Total, serious adverse events | 4 / 4 | 2 / 4 | 2 / 3 | 9 / 12 | 3 / 5 |
Outcome results
Primary
Phase 1: Incidence of Dose Limiting Toxicities (DLTs)
A DLT is defined as: * Grade 4 or 5 events determined by the Investigator to be related to the investigational product, with the exception of Grade 4 laboratory abnormalities that are rapidly reversible or correctable without substantial safety concerns. * Grade ≥3 TAC T cell-associated acute infusion reactions persisting for ≥24 hours * Grade ≥3 TAC T cell-associated CRS or neurotoxicity persisting for ≥72 hours * Grade ≥3 cardiovascular or pulmonary toxicity persisting for ≥72 hours * Grade ≥3 immune-related toxicities * Grade ≥3 organ toxicities or non-hematologic toxicities that do not improve to baseline within 7 days * Clinically consequential Grade ≥3 neutropenia or thrombocytopenia lasting ≥30 days from TAC01-HER2 administration. Clinically consequential is defined as febrile neutropenia, serious infection, or bleeding events.
Time frame: 28 days
Population: One participant at DL4 was classified as non-evaluable due to a fatal aspiration pneumonia event (unrelated to TAC01-HER2) before the DLT period elapsed.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TAC01-HER2 DL1 | Phase 1: Incidence of Dose Limiting Toxicities (DLTs) | Yes | 0 Participants |
| TAC01-HER2 DL1 | Phase 1: Incidence of Dose Limiting Toxicities (DLTs) | No | 4 Participants |
| TAC01-HER2 DL2 | Phase 1: Incidence of Dose Limiting Toxicities (DLTs) | No | 4 Participants |
| TAC01-HER2 DL2 | Phase 1: Incidence of Dose Limiting Toxicities (DLTs) | Yes | 0 Participants |
| TAC01-HER2 DL3 | Phase 1: Incidence of Dose Limiting Toxicities (DLTs) | Yes | 0 Participants |
| TAC01-HER2 DL3 | Phase 1: Incidence of Dose Limiting Toxicities (DLTs) | No | 3 Participants |
| TAC01-HER2 DL4 | Phase 1: Incidence of Dose Limiting Toxicities (DLTs) | Yes | 1 Participants |
| TAC01-HER2 DL4 | Phase 1: Incidence of Dose Limiting Toxicities (DLTs) | No | 10 Participants |
Secondary
Phase 1 and Phase 2: Tmax of TAC01-HER2 (PK)
Defined as the the first study day the Cmax is reached
Time frame: Pre-treatment, days 3, 4 or 5, 8, 11, 14 or15, 18, 21 or 22, 25, 29, 42, months 3, 6, 9, 12, 18, 24 or end of study, and at the confirmatory progressive disease visit
Population: One subject at DL4 was non-evaluable.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| TAC01-HER2 DL1 | Phase 1 and Phase 2: Tmax of TAC01-HER2 (PK) | 4 days after infusion |
| TAC01-HER2 DL2 | Phase 1 and Phase 2: Tmax of TAC01-HER2 (PK) | 18.5 days after infusion |
| TAC01-HER2 DL3 | Phase 1 and Phase 2: Tmax of TAC01-HER2 (PK) | 15 days after infusion |
| TAC01-HER2 DL4 | Phase 1 and Phase 2: Tmax of TAC01-HER2 (PK) | 8 days after infusion |
Secondary
Phase 1: Cmax of TAC01-HER2 (Pharmacokinetics; PK)
Defined as the maximum concentration of TAC T cells after infusion; assessed by vector copy number
Time frame: Pre-treatment, days 3, 4 or 5, 8, 11, 14 or15, 18, 21 or 22, 25, 29, 42, months 3, 6, 9, 12, 18, 24 or end of study, and at the confirmatory progressive disease visit
Population: One subject at DL4 was non-evaluable.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| TAC01-HER2 DL1 | Phase 1: Cmax of TAC01-HER2 (Pharmacokinetics; PK) | 75.5 vector copy number/μg gDNA |
| TAC01-HER2 DL2 | Phase 1: Cmax of TAC01-HER2 (Pharmacokinetics; PK) | 247 vector copy number/μg gDNA |
| TAC01-HER2 DL3 | Phase 1: Cmax of TAC01-HER2 (Pharmacokinetics; PK) | 63 vector copy number/μg gDNA |
| TAC01-HER2 DL4 | Phase 1: Cmax of TAC01-HER2 (Pharmacokinetics; PK) | 797 vector copy number/μg gDNA |
Secondary
Phase 1: Determine Recommended Phase 2 Dose (RP2D) for TAC01-HER2 Monotherapy
RP2D was determined by the Data and Safety Monitoring Committee using the keyboard design method (\<95% chance that the DLT rate exceeds 30%).
Time frame: Up to 28 Days Post TAC01-HER2 infusion
Population: One subjects was classified as non-evaluable due to a fatal aspiration pneumonia event (unrelated to TAC01-HER2) before the period lapsed
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| TAC01-HER2 DL1 | Phase 1: Determine Recommended Phase 2 Dose (RP2D) for TAC01-HER2 Monotherapy | 7000000 TAC01-HER2 cells/kg |
Secondary
Phase 1: Evaluate Disease Control Rate (DCR)
Defined as the percentage of treated subjects with stable disease (SD), PR, and CR as assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST)Version 1.1.
Time frame: 24 months
Population: One subject at DL4 was classified as non-evaluable due to a fatal aspiration pneumonia event (unrelated to TAC01-HER2) before the first scheduled follow-up assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TAC01-HER2 DL1 | Phase 1: Evaluate Disease Control Rate (DCR) | 0 Participants |
| TAC01-HER2 DL2 | Phase 1: Evaluate Disease Control Rate (DCR) | 3 Participants |
| TAC01-HER2 DL3 | Phase 1: Evaluate Disease Control Rate (DCR) | 2 Participants |
| TAC01-HER2 DL4 | Phase 1: Evaluate Disease Control Rate (DCR) | 6 Participants |
Secondary
Phase 1: Evaluate Duration of Response (DoR)
Defined as time from first response to disease progression, end of study, start of another anticancer therapy, or death
Time frame: 24 months
Population: One subject at DL4 was classified as non-evaluable due to a fatal aspiration pneumonia event (unrelated to TAC01-HER2) before the first scheduled follow-up assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| TAC01-HER2 DL1 | Phase 1: Evaluate Duration of Response (DoR) | 0 months |
| TAC01-HER2 DL2 | Phase 1: Evaluate Duration of Response (DoR) | 2.2 months |
| TAC01-HER2 DL3 | Phase 1: Evaluate Duration of Response (DoR) | 0 months |
| TAC01-HER2 DL4 | Phase 1: Evaluate Duration of Response (DoR) | 1.9 months |
Secondary
Phase 1: Evaluate Overall Response Rate (ORR)
Defined as the percentage of treated subjects with a complete or partial response (CR or PR) as assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Time frame: 24 months
Population: One subject at DL4 was classified as non-evaluable due to a fatal aspiration pneumonia event (unrelated to TAC01-HER2) before the first scheduled follow-up assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TAC01-HER2 DL1 | Phase 1: Evaluate Overall Response Rate (ORR) | 0 Participants |
| TAC01-HER2 DL2 | Phase 1: Evaluate Overall Response Rate (ORR) | 1 Participants |
| TAC01-HER2 DL3 | Phase 1: Evaluate Overall Response Rate (ORR) | 0 Participants |
| TAC01-HER2 DL4 | Phase 1: Evaluate Overall Response Rate (ORR) | 1 Participants |
Secondary
Phase 1: Evaluate Overall Survival (OS)
Defined as participants alive after 6 months
Time frame: 6 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TAC01-HER2 DL1 | Phase 1: Evaluate Overall Survival (OS) | 2 Participants |
| TAC01-HER2 DL2 | Phase 1: Evaluate Overall Survival (OS) | 4 Participants |
| TAC01-HER2 DL3 | Phase 1: Evaluate Overall Survival (OS) | 1 Participants |
| TAC01-HER2 DL4 | Phase 1: Evaluate Overall Survival (OS) | 7 Participants |
Secondary
Phase 1: Progression-Free Survival (PFS) or Time to Progression (TTP)
Defined as time from infusion to disease progression or death from any cause
Time frame: 24 months
Population: One participant at DL2 withdrew consent before disease progression and was thus unevaluable for PFS.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| TAC01-HER2 DL1 | Phase 1: Progression-Free Survival (PFS) or Time to Progression (TTP) | 0.9 months |
| TAC01-HER2 DL2 | Phase 1: Progression-Free Survival (PFS) or Time to Progression (TTP) | 2.8 months |
| TAC01-HER2 DL3 | Phase 1: Progression-Free Survival (PFS) or Time to Progression (TTP) | 2.6 months |
| TAC01-HER2 DL4 | Phase 1: Progression-Free Survival (PFS) or Time to Progression (TTP) | 0.95 months |